Tumor heterogeneity and strategies to overcome kinase inhibitor resistance in cancer: lessons from melanoma (Q34802932)

4 August 2017

0 references

Tumor heterogeneity and strategies to overcome kinase inhibitor resistance in cancer: lessons from melanoma (English)

1 reference

4 August 2017

Vito W Rebecca

1

1 reference

4 August 2017

Keiran Sm Smalley

series ordinal

2

1 reference

4 August 2017

language of work or name

English

0 references

publication date

1 February 2011

1 reference

Expert Opinion on Investigational Drugs

4 August 2017

published in

1 reference

4 August 2017

volume

20

1 reference

4 August 2017

issue

2

1 reference

4 August 2017

page(s)

137-140

1 reference

Mechanisms of drug resistance in kinases

4 August 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3078022

Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3078022

COT drives resistance to RAF inhibition through MAP kinase pathway reactivation

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3078022

BRAF gene amplification can promote acquired resistance to MEK inhibitors in cancer cells harboring the BRAF V600E mutation

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3078022

MEK-independent survival of B-RAFV600E melanoma cells selected for resistance to apoptosis induced by the RAF inhibitor PLX4720.

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3078022

Inhibition of Mutated, Activated BRAF in Metastatic Melanoma

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3078022

Recovery of phospho-ERK activity allows melanoma cells to escape from BRAF inhibitor therapy.

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3078022

A temporarily distinct subpopulation of slow-cycling melanoma cells is required for continuous tumor growth

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3078022

A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3078022

RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3078022

MEK1 mutations confer resistance to MEK and B-RAF inhibition

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3078022

Coexisting NRAS and BRAF mutations in primary familial melanomas with specific CDKN2A germline alterations

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3078022

Genetic subgrouping of melanoma reveals new opportunities for targeted therapy

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3078022

Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3078022

Multiple signaling pathways must be targeted to overcome drug resistance in cell lines derived from melanoma metastases

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3078022

Mutually exclusive NRASQ61R and BRAFV600E mutations at the single-cell level in the same human melanoma

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3078022

Melanoma--an unlikely poster child for personalized cancer therapy.

8 July 2018

1 reference

Crossref

https://api.crossref.org/works/10.1517%2F13543784.2011.546218

Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1517%2F13543784.2011.546218

Hyperactivation of MEK–ERK1/2 signaling and resistance to apoptosis induced by the oncogenic B-RAF inhibitor, PLX4720, in mutant N-RAS melanoma cells

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3078022

10.1517/13543784.2011.546218

26 October 2018

Identifiers

DOI

1 reference

4 August 2017

1 reference

4 August 2017

1 reference